GENE FUSIONS AND GENE VARIANTS ASSOCIATED WITH CANCER
The disclosure provides gene fusions, gene variants, and novel associations with disease states, as well as kits, probes, and methods of using the same.
1 - 4 . (canceled)
5 . A method of detecting bladder urothelial carcinoma, breast carcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, glioblastoma multiforme, clear cell renal cell carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, brain lower grade glioma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, prostate adenocarcinoma, rectal cutaneous melanoma, and thyroid gland carcinoma in a sample, the method comprising:
amplifying a nucleic acid comprising a sequence selected from SEQ ID NOs: 1-257; and
detecting the presence of the nucleic acid comprising a sequence selected from SEQ ID NOs: 1-257;
wherein detecting the nucleic acid comprising a sequence selected from SEQ ID NOs: 1-257, indicates that bladder urothelial carcinoma, breast carcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, glioblastoma multiforme, clear cell renal cell carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, brain lower grade glioma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, prostate adenocarcinoma, rectal cutaneous melanoma, and thyroid gland carcinomas present in the sample.
6 . The method of claim 1 , further comprising a kit comprising a set of probes that specifically hybridize to a nucleic acid comprising a break point from Tables 4-6, 20, and 23.
7 . The method of claim 1 , further comprising a set of probes that specifically hybridize to a nucleic acid comprising a break point from Tables 4-6, 20, and 23.
8 - 29 . (canceled)
30 . A method comprising contacting a nucleic acid sample from a patient with a reaction mixture comprising two primers, wherein a first primer is complementary to one gene and a second primer is complementary to a second gene, wherein the fusion of the first gene and the second gene is detectable by the presence of an amplicon generated by the first primer and the second primer, wherein the fusion breakpoint is one of the breakpoints of Table 4, Table 5, Table 6, Table 20, or Table 23, and wherein a patient with an amplicon is administered one or more of the drugs in Table 8, Table 16, Table 17, Table 21, or Table 24.
31 - 36 . (canceled)
37 . A system, comprising:
a nucleic acid amplifier configured to amplify a nucleic acid comprising at least one gene fusion from Tables 1-3, 19, and 22 from a sample, to yield an amplified nucleic acid;
a detector configured to detect the presence of the at least one gene fusion in the amplified nucleic acid by at least one of (i) contacting the composition with at least one probe, wherein each probe specifically hybridizes to the nucleic acid, or (ii) observing the presence of a non-natural or non-native chemical structure in the nucleic acid, and further configured to transmit a detection indication; and
a computer system configured to receive the detection indication and determine that at least one cancer from Tables 1-3, 19, and 22 is present in the sample, based on the detection indication.
38 - 54 . (canceled)